1	Automated Western immunoblotting detection of anti-SARS-CoV-2
2	serum antibodies.
3	
4	Running title: SARS-CoV-2 Western immunoblotting.
5	
6	Edouard, S. <sup>1,2</sup> , Jaafar, R. <sup>1,2</sup> , Orain, N. <sup>1</sup> , Parola, P. <sup>1,3</sup> , Colson, P. <sup>1,2</sup>
7	La Scola, B. <sup>1,2</sup> , Fournier, P-E. <sup>1,3</sup> , Raoult, D. <sup>1,2</sup> , Drancourt, M. <sup>1,2</sup> *
8	
9	Affiliations:
10	<sup>1</sup> IHU-Méditerranée Infection, Marseille, France
11	<sup>2</sup> Aix Marseille Univ., IRD, AP-HM, MEPHI, Marseille, France
12	<sup>3</sup> Aix Marseille Univ., IRD, AP-HM, SSA, VITROME, Marseille, France
13	
14	*Corresponding author : Michel Drancourt, IHU Méditerranée Infection, 19-21
15	boulevard Jean Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33
16	413 732 402; email: michel.drancourt@univ-amu.fr
17	
18	Keywords : SARS-CoV-2, COVID-19, cross-reactivity, serology, automated Western
19	immunoblotting
20	
21	Word count: 2475 words

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 22 ABSTRACT

ELISA and chemiluminescence serological assays for COVID-19 are currently 23 incorporating only one or two SARS-CoV-2 antigens. We developed an automated 24 Western immunoblotting as a complementary serologic assay for COVID-19. The 25 Jess<sup>™</sup> Simple Western system, an automated capillary-based assay was used, 26 incorporating an inactivated SARS-CoV-2 lineage 20a strain as antigen, and IgT 27 28 detection. In total, 602 sera were tested including 223 from RT-PCR-confirmed COVID-19 patients, 76 from patients diagnosed with seasonal HCoVs and 303 from 29 30 coronavirus-negative control sera. We also compared this assay with the EUROIMMUN® SARS-CoV-2 IgG ELISA kit. Among 223 sera obtained from RT-31 PCR-confirmed COVID-19 patients, 180/223 (81%) exhibited reactivity against the 32 nucleocapsid and 70/223 (31%) against the spike protein. Nucleocapsid reactivity 33 was further detected in 9/76 (14%) samples collected from patients diagnosed with 34 seasonal HCoVs and in 15/303 (5%) coronavirus-negative control samples. In the 35 subset of sera collected more than 2 weeks after the onset of symptoms, the 36 sensitivity was 94% and the specificity 93%, the latter value probably reflecting 37 cross-reactivity of SARS-CoV-2 with other coronaviruses. The automated Western 38 immunoblotting presented a substantial agreement (90%) with the compared ELISA 39 (Cohen's Kappa=0.64). Automated Western immunoblotting may be used as a 40 second line test to monitor exposition of people to HCoVs including SARS-CoV-2. 41

#### 42 1. INTRODUCTION

43	To date, seven coronaviruses have been reported as human pathogens,
44	including four seasonal coronaviruses (Alphacoronavirus 229E and NL63 and
45	Betacoronavirus HKU1 and OC43) here referred to as HCoVs, which are associated
46	to mild-to-severe upper and lower respiratory tract infections (1). Two other
47	betacoronaviruses that caused severe acute respiratory syndrome in 2002 in China
48	(SARS-CoV) and the Middle East Respiratory Syndrome in 2012 in Saudi Arabia
49	(MERS-CoV) (2); and the Betacoronavirus SARS-CoV-2 that is the agent of the
50	COVID-19 pandemic has been demonstrated to infect a variety of animals and
51	humans (3). The latter is phylogenetically closely related to HCoV-HKU1 and
52	presents a high sequence homology with SARS-CoV (2).
53	Serological assays used to explore exposition to seasonal HCoVs have
54	previously indicated cross-immunity between all coronaviruses (4–6). SARS-CoV-2
55	exhibits several antigens eliciting a serological response in COVID-19 patients,
56	including spike glycoprotein, its N-terminal (S1) and C-terminal (S2) subunits as well
57	as nucleocapsid (7). Most of routinely used serological COVID-19 assays
58	incorporated only one recombinant protein (8–10). Second generation assays are
59	combining two antigens to increase sensitivity and mostly specificity (7, 11).
60	We developed an automated Western immunoblotting (AWB) assay in order
61	to characterize serological responses to SARS-CoV-2 and the potential cross-
62	reactivity with HCoVs.
63	
64	2. PATIENTS AND METHODS
65	Serum sample collections. A first set of 27 serum samples from 27 different

66 patients with RT-PCR-documented COVID-19 (12), collected at least 2 weeks after

the onset of symptoms were incorporated as a positive control group. All of them 67 presented IgG titer  $\geq$  1:100 using in-house indirect immunofluorescence assay (IFA) 68 (13). Of these, 16 serum samples were used for conventional immunoblotting 69 including 3 samples exhibiting low (1:200), moderate (1:800) and high (1:3,200) IgG 70 titers using IFA that were used to fix optimal conditions to be used for AWB (antigen, 71 serum and secondary antibodies concentrations). One serum collected in 2018, 72 before the onset of COVID-19 (negative RT-PCR for HCoVs on homologous 73 respiratory specimen) was included as negative control. 74

75 As for AWB, 223 serum samples (including the 27 serum samples described above) collected from 223 different RT-PCR-confirmed COVID-19 patients were 76 incorporated as a positive control group. Twenty-seven of these sera were tested for 77 antibodies to the recombinant S1 protein by EUROIMMUN® SARS-CoV-2 IgG 78 ELISA (Euroimmun, Bussy Saint-Martin, France) performed using the Elispeed DUO 79 system (Euroimmun) according to the manufacturer's recommendations. The ratio 80 (AUC sample/AUC calibrator) was interpreted as follows: <0.8 negative; ≥0.8 to <1.0 81 undetermined; ≥1.1 positive. We considered undetermined results as negative for 82 statistical analyses. A negative control group (37 serum samples) consisted of (i) 10 83 serum sampled obtained less than 5 days after the onset of symptoms) in patients 84 presenting high viral loads of SARS- CoV-2 (Ct values < 20); (ii) 14 sera from 85 asymptomatic healthcare workers largely exposed to the virus but exhibiting negative 86 results for RT-PCR and serology by IFA for SARS-CoV-2 during follow-up; and (iii) 87 13 sera from patients collected in 2019 before the pandemic and harbouring 88 negative RT-PCR results for the 4 HCoVs in their nasopharyngeal specimens. These 89 37 serum samples were also all tested by ELISA. A third group of 76 serum samples 90 was retrieved from patients diagnosed with seasonal coronavirus infections (HCoV-91

NL63 (n=19), HCoV-OC43 (n=21), HCoV-229E (n=8) and HCoV-HKU1 (n=28)) and 92 were collected at least 2 weeks after the diagnosis, of which 45 were also tested by 93 ELISA. A fourth group of 266 sera was collected from children and adults admitted in 94 surgery departments (n=145) and other medical units (=121) before the pandemic, of 95 which 88 serum samples were also tested by ELISA; their HCoVs status was 96 unknown. Altogether, 197 sera tested by ELISA, included 27 sera from COVID-19-97 98 positive patients and 170 from COVID-19-negative patients. All sera were retrospectively tested and no sample was collected specifically for this study which 99 100 was approved by our institution's ethics committee under No.2020-024. 101 Virus growth, purification and concentration. The SARS-CoV-2 IHUMI2 strain 102 103 (lineage 20a) was used as antigen as previously described (13). One liter of infected cells was collected and clarified by centrifugation at 700 x g for 10 min and by 104 filtering the supernatant through a 0.45-µm pore-sized filter and further a 0.2-µm 105 pore-sized filter. Virions were then aggregated by overnight precipitation at 4°C with 106 10% polyethylene glycol 8000 white flake type (PEG-8000, BioUltra, SIGMA-107 ALDRICH, USA) and 2.2% crystalline NaCl, with gentle swirling. Precipitated virus 108 particles were then centrifuged at 10,000 x g for 30 min using a SORVALL Evolution 109 centrifuge with SLA-3000 Recent 1 fixed angle rotor pre-cooled at 4°C (Kendro 110 111 Laboratory Products, Newtown, USA). The pellet was resuspended with HEPESsaline (0.9% NaCl, 10 mL of 1 M HEPES, 990 mL purified water) previously vacuum-112 sterilized through a 0.2-µm pore size membrane; swirled in the cold HEPES-saline 113 until dissolution to avoid using pipetting as it may hurts viral spikes at this step. The 114 resuspended pellet was then treated with a 30% sucrose cushion in 25 x 89 mm 115 centrifuge tubes (Ultra-Clear, BECKMAN COULTER, CA, USA). Final purification 116

was achieved by ultracentrifugation at 100,000 x g for 90 min at 4°C followed by two 30-min washes with HBSS using SORVALL Discovery 90SE with Surespin 630 rotor (Kendro Laboratory Products). The final pellet was resuspended in 400  $\mu$ L of HEPES-buffered saline and heat-inactivated at 65°C for 1h.

121

Conventional Western immunoblotting. SARS-CoV-2 antigens diluted to 0.5 122 mg/mL were mixed (v/v) with 2X Laemmli Sample Buffer (Bio-Rad, Hercules, CA, 123 USA) before a heating step of 5 min at 95°C. This preparation and a ladder were 124 125 dispensed in wells shaped in a 5 % polyacrylamide stacking gel. The protein separation was then performed in a 10 % polyacrylamide separating gel with a Mini 126 Trans-blot cell device (Bio-Rad) at 160 V for 90 min. After transferring proteins from 127 the gel to a 0.45 µm-pore size nitrocellulose membrane (Bio-Rad) at 100 V and 15°C 128 for 90 min, the membrane was left at 4°C overnight with 5% non-fat milk powder in 129 TBS buffer. Blocked strips were incubated with sera diluted at 1:50 for 60 min. Three 130 washes of 10 min were performed before a 90-min incubation of the strips with goat 131 peroxidase-conjugated anti-human IgG/ IgM/IgA (Jackson ImmunoResearch, Ely, 132 UK) diluted 1:1000. Three washes of 10 min with TBS buffer were made. Strips were 133 put in contact with ECL Western Blotting Substrate (Promega, Madison, USA) and 134 the reaction with secondary antibody peroxydases was revelated with a Fusion Fx 135 chemiluminescence imaging system and analysed with the Fusion software (Vilber, 136 Marne-la-Vallée, France). 137

138

Automated Western immunoblotting. The Jess<sup>™</sup> Simple Western system
 (ProteinSimple, San Jose CA, USA,) is an automated capillary-based size separation
 and nano-immunoassay system. To quantify the absolute serological response to

viral antigens, we followed the manufacturer's standard method for 12-230-kDa Jess 142 separation module (SM-W004). The SARS-CoV-2 antigen (1 µg/µL) was mixed with 143 0.1X Sample buffer and Fluorescent 5X Master mix (ProteinSimple) to achieve a 144 final concentration of 0.25 µg/µL in the presence of fluorescent molecular weight 145 markers and 400 mM dithiothreitol (ProteinSimple). This preparation was denatured 146 at 95°C for 5 minutes. Ladder (12-230-kDa PS-ST01EZ) and SARS-CoV-2 proteins 147 148 were separated in capillaries as they migrated through a separation matrix at 375 volts. A ProteinSimple proprietary photoactivated capture chemistry was used to 149 150 immobilize separated viral proteins on the capillaries. Patients sera diluted at a 1:2 were added and incubated for 60 min. After a wash step, goat HRP-conjugated anti-151 human IgG/IgM/IgA antibodies (Jackson ImmunoResearch) diluted 1:500 was added 152 for 30 min. The chemiluminescent revelation was established with peroxyde/luminol-153 S (ProteinSimple). Digital image of chemiluminescence of the capillary was captured 154 with Compass Simple Western software (version 4.1.0, Protein Simple) that 155 calculated automatically heights (chemiluminescence intensity), area and 156 signal/noise ratio. Results could be visualized as electropherograms representing 157 peak of chemiluminescence intensity and as lane view from signal of 158 chemiluminescence detected in the capillary. An internal system control was 159 included in each run. 160

161

Statistical analysis. ROC curves were performed using XL stat. The agreement rate and Cohen's Kappa value were determined for agreement between ELISA and AWB. For data comparisons and statistical analyses, the Fisher's exact test, Chisquared test, Mann-Witney test and standard statistical software (GraphPad Prism v7) were used. A p-value < 0.05 was considered statistically significant.</p>

#### 167 3. RESULTS

168	Fixing automated Western immunoblotting parameters. Protein profiles of the
169	purified SARS-CoV-2 antigen and uninfected Vero cells were verified on silver-
170	stained 2-D gel. As expected, the viral specific and major dominant proteins were N,
171	S, S1 and S2 proteins at 42, 170, 110 and 90 kDa, respectively. All 16 serum
172	samples collected from 16 different COVID-19 patients exhibited reactivity against
173	the nucleocapsid and spike proteins. Parameter optimization to translate these data
174	on AWB included an antigen concentration of 0.25 $\mu g/\mu L,$ a serum dilution at 1:2 and
175	a secondary antibody dilution of 1:500 (data not shown). In these conditions, AWB of
176	positive serum samples yielded a prominent 56-kDa band interpreted as the
177	nucleocapsid and a 217-kDa band interpreted as the spike protein (Figure S1).
178	Higher molecular weight values observed with AWB than with SDS-PAGE were due
179	to the different composition of gel in the capillaries. In total, the 16 sera from COVID-
180	19 patients tested with conventional and AWB gave similar results except that AWB
181	failed to detect the spike protein in one sample. Further, AWB yielded significant
182	higher S/N ratio, pick height and area under curve for the nucleocapsid ( $p < 0.0001$ )
183	and spike proteins ( $p < 0.0001$ ) in the 27 serum samples from COVID-19 patients
184	than in 37 serum samples collected in negative control patients (Table 1). The S/N
185	ratio presented higher Youden Index for nucleocapsid detection, being therefore
186	interpreted as the most pertinent parameter to interpret AWB results. Optimal
187	threshold for the S/N ratio of 110.4 conferred a 96.3% sensitivity and 94.6%
188	specificity for the nucleocapsid detection. Determination of a cut-off to interpret
189	results of spike protein was not useful and could be based only on
190	presence/absence of signal with sensitivity to 66.7% and 100% specificity (Table 2).

Therefore, we further used the presence of antibodies to the nucleocapsid with S/N ratio  $\geq$  110.4 and/or to the spike protein, as criteria to define a positive AWB.

193

Automated Western immunoblotting results. AWB yielded 395/602 (66%) 194 negative and 207/602 (34%) positive serum samples (Table 3); giving an 81% 195 sensitivity as 181/223 COVID-19 patients were positive (nucleocapsid detected in 196 197 180/223 (76%) and spike in 67/223 (30%), respectively); and a 93% specificity as 26/379 (7%) non-COVID-19 patients were positive; applying above reported cut-off 198 199 criteria (Figures 1 and 2a). Accordingly, positive (PPV) and negative predictive values (NPV) were of 87% and 89%, respectively. Sera from COVID-19 patients 200 were collected with a median of 13 days (range 0 to 165) after the onset of 201 202 symptoms. Sensitivity was 54% among sera collected less than 10 days after the onset of symptoms and increased to 94% among sera collected more than 10 days 203 after the onset of symptoms (Figure 3). AWB had a 90% agreement with the herein 204 compared ELISA assay (Cohen's Kappa=0.64) as the latter was positive in 22/27 205 (81.5%) COVID-19 patients and 6/170 (3.5%) non-COVID-19 patients, yielding a 206 sensitivity of 81.5% and specificity of 97% (Table 4). 207

Detailing false-positive AWB, antibodies to the nucleocapsid were detected in 208 3/37 (8%) negative control serum samples. Also, 9/76 (14%) serum sampled from 209 210 patients diagnosed with seasonal HCoVs, reacted with the nucleocapsid which was detected in 5/28 (18%) of patients with HCoV-HKU1, 2/19 (10.5%) with HCoV-NL63, 211 2/21 (9.5%) with HCoV-OC43 but in none of HCoV-229E patients (Figure 2b). In 212 addition, one HCoV-HKU1 serum and one HCoV-NL63 serum reacted against the 213 spike protein, increasing the number of total cross-reactions to 11/76 (14.5%) for this 214 group. Among 266 serums sampled before the COVID-19 epidemic in France, albeit 215

of unknown status for HCoVs, 12/266 (4.5%) reacted against the nucleocapsid but
none against the spike protein.

Most cross reactivities were detected in 46-65-year-old patients (7/63) and more than 65-year-old (4/43) patients (Figure 2c). Cross reactivity was more prevalent in subjects > 21 years (15/173) than in children  $\leq$  15 years (6/126) but this difference was not significant (*p* = 0.25, Fisher's exact test).

222

#### 4. DISCUSSION

224 An AWB, incorporating whole SARS-CoV-2 viral particles, was demonstrate to be efficient in detecting specific antibodies against SARS-CoV-2 dual nucleocapsid 225 and spike proteins, achieving a 87% PPV and a 89% NPV for COVID-19, in the 226 population tested in this study. Accordingly, dual nucleocapsid and spike protein 227 detections exhibited 81% sensitivity and 93% specificity. Indeed, the spike protein 228 was detected in only two non-COVID-19 patients whereas the nucleocapsid protein 229 was detected in 24 non-COVID-19 patients, including 11 patients diagnosed with 230 HCoVs. In our study, AWB results were consistent with results obtained using a 231 commercially ELISA incorporating recombinant spike-1 protein. The serological 232 observations obtained in this study therefore indicated that it is worth developing 233 next generation serological assays incorporating both the nucleocapsid and the 234 235 spike proteins, in order to achieve almost 100% sensitivity and 100% specificity of SARS-CoV-2 infection, which is not the situation with first generation, commercially-236 available serological assays (7, 11, 14). 237

It should be noted that cross-reactivity was more prevalent in patients infected
with other betacoronaviruses (accounting for 31% of cross-reactivity) than in patients
infected with alphacoronaviruses (accounting for 12% of cross-reactivity); being

mainly supported by SARS-CoV-2 nucleocapsid (in 92% of cross-reacting serum 241 samples); and mostly found in adult patients older than 46 years (accounting for 52% 242 of sera with cross-reactivity). Our observations are consistent with previous reports 243 that cross-reactions were observed with nucleocapsid while serological assays 244 incorporating the spike protein have been reported to be more specific but less 245 sensitive (4–6, 15–18). Cross-reactivity has been described between endemic 246 247 coronaviruses and SARS-CoV-2 (19). Several studies reported the presence of antibodies reacting with SARS-CoV-2 spike and nucleocapsid proteins in serum 248 249 sampled before the pandemic and in HCoVs patients (20, 21).

In a few previous reports of the described AWB (22-24), a recombinant 250 protein was used as the antigen whereas we used purified virus antigen directly 251 produced in the biosafety level 3 laboratory (13). This fact could explain in part the 252 important difference of sensitivity for the spike protein compared to the nucleocapsid, 253 in our assay. Thereby, serum dilution was a critical parameter as the spike protein 254 was detected only for a low, 1:2 dilution of serum. Nevertheless, the herein 255 described AWB assay demonstrated a better standardization and reproducibility than 256 conventional Western immunoblotting, proved to be user-friendly and enabled 257 analyzing 24 serum samples in less than 4 hours. Result interpretation was not only 258 259 based on presence/absence and intensity of bands but a chemiluminescent image was automatically analyzed with software allowing noise reduction. The "virtual 260 image" of reactions present in the capillaries could be represented by peaks on 261 electropherogram or lane views. 262

In conclusion, the herein described AWB may be incorporated as a first line serological test for the diagnosis of exposure to SARS-CoV-2 if limited series have to be investigated; or as a second-line assay to confirm or exclude the diagnosis of

- 266 COVID-19 especially in patients with negative, doubtful and discrepant RT-PCR
- results, and may be used to measure past exposition to the virus.
- 268
- 269
- 270

#### 271 ACKNOWLEDGMENTS

- 272 The authors acknowledge the contribution of the technical staff of the IHU
- 273 Méditerranée Infection Laboratory. This work was supported by IHU Méditerranée
- 274 Infection, Marseille, France. RJ benefits from a PhD grant by fondation Mediterranée
- 275 Infection, Marseille, France.
- 276

#### 277 FINANCIAL SUPPORT

- 278 This study was funded by ANR-15-CE36-0004-01 and by ANR "Investissements
- d'Avenir" Méditerranée Infection 10-IAHU-03.
- 280

#### 281 DECLARATION OF COMPETING INTEREST

- None to declare.
- 283
- 284

### 285 **REFERENCES**

286	1.	Zimmermann P, Curtis N. 2020. Coronavirus Infections in Children Including
287		COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis,
288		Treatment and Prevention Options in Children. Pediatr Infect Dis J 39:355–368.
289	2.	Coronaviridae Study Group of the International Committee on Taxonomy of
290		Viruses. 2020. The species Severe acute respiratory syndrome-related
291		coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol
292		5:536–544.
293	3.	Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu
294		R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel
295		Coronavirus Investigating and Research Team. 2020. A Novel Coronavirus from
296		Patients with Pneumonia in China, 2019. N Engl J Med 382:727–733.
297	4.	Maache M, Komurian-Pradel F, Rajoharison A, Perret M, Berland J-L, Pouzol S,
298		Bagnaud A, Duverger B, Xu J, Osuna A, Paranhos-Baccalà G. 2006. False-
299		positive results in a recombinant severe acute respiratory syndrome-associated
300		coronavirus (SARS-CoV) nucleocapsid-based western blot assay were rectified
301		by the use of two subunits (S1 and S2) of spike for detection of antibody to
302		SARS-CoV. Clin Vaccine Immunol 13:409–414.
303	5.	Woo PCY, Lau SKP, Wong BHL, Chan K-H, Hui W-T, Kwan GSW, Peiris JSM,
304		Couch RB, Yuen K-Y. 2004. False-positive results in a recombinant severe
305		acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid
306		enzyme-linked immunosorbent assay due to HCoV-OC43 and HCoV-229E

rectified by Western blotting with recombinant SARS-CoV spike polypeptide. J
 Clin Microbiol 42:5885–5888.

309 6. Che X-Y, Qiu L-W, Liao Z-Y, Wang Y, Wen K, Pan Y-X, Hao W, Mei Y-B,

310 Cheng VCC, Yuen K-Y. 2005. Antigenic cross-reactivity between severe acute

respiratory syndrome-associated coronavirus and human coronaviruses 229E

and OC43. J Infect Dis 191:2033–2037.

313 7. Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S, Strich JR,

314 Chertow DS, Davey RT, Cohen JI. 2020. Sensitivity in Detection of Antibodies

to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome

316 Coronavirus 2 in Patients With Coronavirus Disease 2019. J Infect Dis 222:206–

317 213.

8. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S,

Adriano A, Beese S, Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ,

320 Dittrich S, Emperador D, Hooft L, Leeflang MM, Van den Bruel A, Cochrane

321 COVID-19 Diagnostic Test Accuracy Group. 2020. Antibody tests for

identification of current and past infection with SARS-CoV-2. Cochrane

323 Database Syst Rev 6:CD013652.

9. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, Dela Cruz CS, Wang Y, Wu

325 C, Xiao Y, Zhang L, Han L, Dang S, Xu Y, Yang Q-W, Xu S-Y, Zhu H-D, Xu Y-

326 C, Jin Q, Sharma L, Wang L, Wang J. 2020. Profiling Early Humoral Response

to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis 71:778–

328 785.

329	10. Liu Z-L, Liu Y, Wan L-G, Xiang T-X, Le A-P, Liu P, Peiris M, Poon LLM, Zhang
330	W. 2020. Antibody Profiles in Mild and Severe Cases of COVID-19. Clin Chem
331	66:1102–1104.

- 11. Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR,
- Goldgof GM, Levine AG, Bapat SP, Stramer SL, Esensten JH, Hightower AW,
- Bern C, Wu AHB. 2020. Magnitude and kinetics of anti-SARS-CoV-2 antibody
- responses and their relationship to disease severity. Clin Infect Dis
- 336 https://doi.org/10.1093/cid/ciaa979.
- 12. Amrane S, Tissot-Dupont H, Doudier B, Eldin C, Hocquart M, Mailhe M,
- 338 Dudouet P, Ormières E, Ailhaud L, Parola P, Lagier J-C, Brouqui P, Zandotti C,
- Ninove L, Luciani L, Boschi C, La Scola B, Raoult D, Million M, Colson P,
- Gautret P. 2020. Rapid viral diagnosis and ambulatory management of
- 341 suspected COVID-19 cases presenting at the infectious diseases referral
- hospital in Marseille, France, January 31st to March 1st, 2020: A respiratory
- virus snapshot. Travel Med Infect Dis 101632.
- 13. Edouard S, Colson P, Melenotte C, Di pinto Fabrizio, Thomas Laurence, La
- 345 Scola B, Million M, Tissot-Dupont, Gautret philippe, Stein A, Brouqui P, Parola
- P, Lagier J-C, Raoult D, Drancourt M. 2020. Evaluating the serological status of
- 347 COVID-19 patients using an indirect immunofluorescent assay, France. Eur J
- Clin Microbiol Infect Dis 1-11 https://doi.org/10.1007/s10096-020-04104-2.

350	14. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. 2020. Brief clinical
351	evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. J Clin Virol
352	129:104480.

15. Meyer B, Drosten C, Müller MA. 2014. Serological assays for emerging

coronaviruses: challenges and pitfalls. Virus Res 194:175–183.

- 16. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu
- Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z. 2020. Characterization of
- 357 spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-
- reactivity with SARS-CoV. Nat Commun 11:1620.
- 17. Marien J, Michiels J, Heyndrickx L, Kerkhof K, Foque N, Widdowson M-A,
- 360 Desombere I, Jansens H, Van Esbroeck M, Arien KK. 2020. Evaluating SARS-
- 361 CoV-2 spike and nucleocapsid proteins as targets for IgG antibody detection in
- 362 severe and mild COVID-19 cases using a Luminex bead-based assay. medRxiv
- 363 preprint 2020. https://doi.org/10.1101/2020.07.25.20161943.
- 18. Van Elslande J, Decru B, Jonckheere S, Van Wijngaerden E, Houben E,
- 365 Vandecandelaere P, Indevuyst C, Depypere M, Desmet S, André E, Van Ranst
- 366 M, Lagrou K, Vermeersch P. 2020. Antibody response against SARS-CoV-2
- 367 spike protein and nucleoprotein evaluated by four automated immunoassays
- 368 and three ELISAs. Clin Microbiol Infect
- 369 https://doi.org/10.1016/j.cmi.2020.07.038.
- 19. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan
- 371 SM, Borgert BA, Moreno CA, Solomon BD, Trimmer-Smith L, Etienne V,
- Rodriguez-Barraquer I, Lessler J, Salje H, Burke DS, Wesolowski A, Cummings

373		DAT. 2020. A systematic review of antibody mediated immunity to
374		coronaviruses: kinetics, correlates of protection, and association with severity.
375		Nat Commun 11:4704.
376	20.	Khan S, Nakajima R, Jain A, de Assis RR, Jasinskas A, Obiero JM, Adenaiye
377		O, Tai S, Hong F, Milton DK, Davies H, Felgner PL, Prometheus Study Group.
378		2020. Analysis of Serologic Cross-Reactivity Between Common Human
379		Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray.
380		BioRxiv Prepr Serv Biol https://doi.org/10.1101/2020.03.24.006544.
381	21.	Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, Ulferts R, Earl
382		C, Wrobel AG, Benton DJ, Roustan C, Bolland W, Thompson R, Agua-Doce A,
383		Hobson P, Heaney J, Rickman H, Paraskevopoulou S, Houlihan CF, Thomson
384		K, Sanchez E, Shin GY, Spyer MJ, Joshi D, O'Reilly N, Walker PA, Kjaer S,
385		Riddell A, Moore C, Jebson BR, Wilkinson M, Marshall LR, Rosser EC,
386		Radziszewska A, Peckham H, Ciurtin C, Wedderburn LR, Beale R, Swanton C,
387		Gandhi S, Stockinger B, McCauley J, Gamblin SJ, McCoy LE, Cherepanov P,
388		Nastouli E, Kassiotis G. 2020. Preexisting and de novo humoral immunity to
389		SARS-CoV-2 in humans. Science https://doi.org/10.1126/science.abe1107.
390	22.	Yeh H-Y, Serrano KV, Acosta AS, Buhr RJ. 2016. Production of recombinant
391		Salmonella flagellar protein, FlgK, and its uses in detection of anti-Salmonella
392		antibodies in chickens by automated capillary immunoassay. J Microbiol
393		Methods 122:27–32.
394	23.	Fourier A, Dorey A, Perret-Liaudet A, Quadrio I. 2018. Detection of CSF 14-3-3
395		Protein in Sporadic Creutzfeldt-Jakob Disease Patients Using a New Automated

Capillary Western Assay. Mol Neurobiol 55:3537–3545.

- 24. Kodani M, Martin M, de Castro VL, Drobeniuc J, Kamili S. 2019. An Automated
- 398 Immunoblot Method for Detection of IgG Antibodies to Hepatitis C Virus: a
- 399 Potential Supplemental Antibody Confirmatory Assay. J Clin Microbiol 57.

400

401

#### 403 Figure Legends.

404

- **Figure 1.** Drawing illustrating (a) overall results of automated Western
- 406 immunoblotting of 602 sera (b) results comparison with commercially available
- 407 ELISA in 197 sera.

408

- **Figure 2.** Signal/noise ratio for the detection of nucleocapsid with automated
- 410 Western immunoblotting: (a) in 602 sera collected from 6 different groups of patients
- (b) in 76 sera collected from non-COVID-19, HCoVs infected patients (c) in 342 sera
- 412 collected before the COVID-19 pandemic, classified by age-group.

413

- 414 **Figure 3.** Automated Western immunoblotting detection of anti-SARS-CoV-2
- 415 antibodies: positive and negative sera according to delay after the onset of
- symptoms. The curve represents the proportion of positive sera (%).

417

- 418
- 419
- 420
- 421
- 422

423

### 425 Supplementary Figure.

- 426 Figure S1. Strips of conventional western immunoblotting (a) and lane view of
- 427 automated Western immunoblotting (b) incubated with serum collected from one
- 428 COVID-19 positive patient quoted "+" and serum collected from one non COVID-19
- 429 patient quoted "-". The first lane represents the molecular mass marker in kDa. (c)
- 430 chromatogram of chemiluminescence intensity detected by Jess<sup>™</sup> Simple Western
- 431 in the capillaries on positive (blue) and negative (green) sera.

432

433

434

		Negativ	_		
	Early sera from COVID-19- positive patients (n=10)	sera from negative HCoVs patients collected before the pandemic (n=13)	sera from healthcare workers highly exposed to SARS-CoV-2 (n=14)	All	sera from COVID-19-positive patients (n=27)
Nucleocapside (56 kDa)					
S/N ratio	44 (29.98-64.4)	62.1 (33-78.7)	49.85 (34.95-70.95)	49.85 (34.95- 70.95)	421 (214.1-666.8)
Height	6511 (5674-7729)	8854 (6428- 12995)	4934 (4397-5605)	6100 (4586-9813)	64065 (32338-121517)
Area	82169 (65588- 94895)	124541 (84495- 147319)	67780 (61427-76234)	79634 (66110- 128111)	839470 (524393-1597656)
Spike (217 kDa)					
S/N	0	0	0	0	27.9 (0-43.1)
Height	0	0	0	0	3174 (0-8621)
Area	0	0	0	0	40699 (0-182108)

Table 1. Automated Western immunoblotting results of 27 sera from COVID-19-positive patients and 37 sera from negative controlsused to fix automated Western immunoblotting parameters. (Results expressed as median with 25 and 75 percentile).

n=64	Ļ	AUC	Youden index	Optimal Cut-off value	Sensitivity (%)	Specificity (%)	True positive (nb)	True negative (nb)	False positive (nb)	False negative (nb)
Nucleoca	pside									
	S/N	0.975	0.907	110.4	96.3	94.6	26	35	2	1
Н	eight	0.982	0.885	24922	88.9	100	24	37	0	3
	Area	0.970	0.885	287005	88.9	100	24	37	0	3
Spike										
	S/N	0.833	0.667	0	66.7	100	18	37	0	9
Н	eight	0.833	0.667	0	66.7	100	18	37	0	9
	Area	0.833	0.667	0	66.7	100	18	37	0	9

Table 2. Sensitivity and specificity of automated Western immunoblotting determined with 27 sera from COVID-19-positivepatients and 37 sera from non COVID-19 patients.

AUC= area under the curve.

		Negative	controls					
	Early sera from COVID- 19 positive patients (n=10)	Sera from negative HCoVs patients collected before the pandemic (n=13)	Sera from healthcare workers highly exposed to SARS-CoV- 2 (n=14)	All (n=37)	Sera from patients diagnosed with others HCoVs (n=76)	Sera collected before the pandemic from patients with unknown status for HCoVs (n=266)	Sera from COVID-19 positive patients (n=223)	Total (n=602)
Positive sera								
Nucleocapside reactivity	1 (10%)	0 (0%)	2 (14)	3 (8)	9 (12)	12 (4.5%)	180 (81)	204 (34)
Spike reactivity	0	0	0	0	2 (3)	0	67 (30)	69 (11%)
Total	1 (10%)	0 (0%)	2 (14)	3 (8)	11 (14.5)	12 (4.5%)	181 (81)	207 (34%)

## Table 3. Results of automated Western immunoblotting including the 602 sera tested.

# Table 4. Comparison between automated Western immunoblotting and commercialSARS-CoV-2 IgG ELISA on 197 sera.

	AWB IgT	ELISA IgG
	Nb (%)	Nb (%)
Sera from COVID-19 positive patients (n=27)	27 (100%)	22 (81%)
Sera from negative control group (n=37)	3 (8%)	0
Early sera from COVID-19 positive patients (n=10)	1 (10%)	0
Sera from healthcare workers highly exposed to SARS-		
CoV-2 (n=14)	2 (14%)	0
Sera from negative HCoVs patients collected before the		
pandemic (n=13)	0	0
Sera from patients diagnosed with others HCoVs (n=45)	6 (13%)	0
Sera collected before the pandemic from patients with	5 (60%)	6 (70%)
unknown status for HCoVs (n=88)	3 (0%)	0(7%)







\* Confirmed by positive RT-PCR for SARS-CoV-2



